Dermatology

Recent research has explored how biologics used to treat atopic dermatitis might increase the risk of developing conjunctivitis. If you have atopic dermatitis and are considering biologic medications, this overview may help you understand potential risks and what to expect. Certain treatments for atopic dermatitis may raise the chance of getting conjunctivitis. The primary treatments...

One of the most extensive epidemiological investigations in the last five decades regarding alopecia areata prevalence and incidence in the United States shows that the burden of the condition is rising, disproportionately affecting females and people living in the Northeast. To overcome health disparities and fight diseases effectively, it is vital to understand the prevalence...

A recent study provides unique insights into alopecia areata presentation in Hispanic/Latinx patients. It found that comorbidities and nutritional deficiencies were common in the group.  To understand health disparities, it is vital to characterize the unmet needs of alopecia areata (AA) patients from various ethnic groups. This retrospective study, published in the Journal of the...

A retrospective study reports that when enrolling patients for alopecia areata clinical trials, Blacks are likelier to fail initial screening and have higher withdrawal or early termination rates.  Hispanic and Black people have a higher incidence of alopecia areata (AA) during their lifetimes compared to White people. However, disease etiology and pathology differences between various...

Greater improvement seen in disease severity by 12 weeks with ciclosporin, but MTX was superior by 60 weeks For children and young people with severe atopic dermatitis (AD), ciclosporin (CyA) and methotrexate (MTX) are both effective over 36 weeks, according to a study published online Sept. 19 in the British Journal of Dermatology. Carsten Flohr, Ph.D.,...

Over-the-counter 1% colloidal oatmeal cream effectively treats mild-to-moderate atopic dermatitis in Black children, according to a recent study. Atopic dermatitis (AD) is one of the most common skin conditions among children in the United States. Its prevalence varies with race and ethnicity, with Black children being 1.7 times more likely to develop AD than White...

Patient race and specific atopic dermatitis diagnoses are associated with differences in dupilumab prescription patterns. Atopic dermatitis (AD) is a common chronic inflammatory disease. Treatment with a systemic immunomodulating agent is indicated in moderate-to-severe AD. These systemic agents include cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, and systemic steroids. Dupilumab, a fully human monoclonal antibody, may be...

Atopic dermatitis severity and treatment patterns do not differ among diverse racial and ethnic groups in the United States, according to a recent study. Atopic dermatitis (AD) has heterogeneous manifestations across regional and racial groups. Previous studies in the United States found racial and ethnic differences in AD disease patterns, including risk factors for severity,...

Air pollutants such as nitrogen dioxide (NO2), carbon monoxide (CO), sulfur dioxide (SO2), and ozone (O3) are linked to the prevalence and severity of atopic dermatitis. These contaminants have been linked to an increased risk of AD during pregnancy, childhood, and maturity. Atopic dermatitis (AD) is a chronic, inflammatory skin disease affecting approximately 20% of...